These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
498 related articles for article (PubMed ID: 9178864)
21. Discriminative behavioral assessment unveils remarkable reactive astrocytosis and early molecular correlates in basal ganglia of 3-nitropropionic acid subchronic treated rats. Cirillo G; Maggio N; Bianco MR; Vollono C; Sellitti S; Papa M Neurochem Int; 2010 Jan; 56(1):152-60. PubMed ID: 19799953 [TBL] [Abstract][Full Text] [Related]
22. The mitochondrial toxin 3-nitropropionic acid induces differential expression patterns of apoptosis-related markers in rat striatum. Vis JC; Verbeek MM; de Waal RM; ten Donkelaar HJ; Kremer B Neuropathol Appl Neurobiol; 2001 Feb; 27(1):68-76. PubMed ID: 11299004 [TBL] [Abstract][Full Text] [Related]
23. Role of matrix metalloproteinase-9 (MMP-9) in striatal blood-brain barrier disruption in a 3-nitropropionic acid model of Huntington's disease. Duran-Vilaregut J; del Valle J; Manich G; Camins A; Pallàs M; Vilaplana J; Pelegrí C Neuropathol Appl Neurobiol; 2011 Aug; 37(5):525-37. PubMed ID: 21175737 [TBL] [Abstract][Full Text] [Related]
24. Riluzole protects from motor deficits and striatal degeneration produced by systemic 3-nitropropionic acid intoxication in rats. Guyot MC; Palfi S; Stutzmann JM; Mazière M; Hantraye P; Brouillet E Neuroscience; 1997 Nov; 81(1):141-9. PubMed ID: 9300407 [TBL] [Abstract][Full Text] [Related]
25. Behavioral and morphological comparison of two nonhuman primate models of Huntington's disease. Roitberg BZ; Emborg ME; Sramek JG; Palfi S; Kordower JH Neurosurgery; 2002 Jan; 50(1):137-45; discussion 145-6. PubMed ID: 11844244 [TBL] [Abstract][Full Text] [Related]
26. The 3-NP Model of Striatal Neurodegeneration. Brouillet E Curr Protoc Neurosci; 2014 Apr; 67():9.48.1-9.48.14. PubMed ID: 24723322 [TBL] [Abstract][Full Text] [Related]
27. Thymoquinone loaded solid lipid nanoparticles counteracts 3-Nitropropionic acid induced motor impairments and neuroinflammation in rat model of Huntington's disease. Ramachandran S; Thangarajan S Metab Brain Dis; 2018 Oct; 33(5):1459-1470. PubMed ID: 29855977 [TBL] [Abstract][Full Text] [Related]
28. Asymmetrical motor behavior in rats with unilateral striatal excitotoxic lesions as revealed by the elevated body swing test. Borlongan CV; Randall TS; Cahill DW; Sanberg PR Brain Res; 1995 Apr; 676(1):231-4. PubMed ID: 7796175 [TBL] [Abstract][Full Text] [Related]
29. Bilateral fetal striatal grafts in the 3-nitropropionic acid-induced hypoactive model of Huntington's disease. Borlongan CV; Koutouzis TK; Poulos SG; Saporta S; Sanberg PR Cell Transplant; 1998; 7(2):131-5. PubMed ID: 9588595 [TBL] [Abstract][Full Text] [Related]
30. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Keene CD; Rodrigues CM; Eich T; Linehan-Stieers C; Abt A; Kren BT; Steer CJ; Low WC Exp Neurol; 2001 Oct; 171(2):351-60. PubMed ID: 11573988 [TBL] [Abstract][Full Text] [Related]
31. Mitochondrial NAD+-linked State 3 respiration and complex-I activity are compromised in the cerebral cortex of 3-nitropropionic acid-induced rat model of Huntington's disease. Pandey M; Varghese M; Sindhu KM; Sreetama S; Navneet AK; Mohanakumar KP; Usha R J Neurochem; 2008 Jan; 104(2):420-34. PubMed ID: 17953654 [TBL] [Abstract][Full Text] [Related]
32. Topological analysis of striatal lesions induced by 3-nitropropionic acid in the Lewis rat. Blum D; Gall D; Cuvelier L; Schiffmann SN Neuroreport; 2001 Jun; 12(8):1769-72. PubMed ID: 11409756 [TBL] [Abstract][Full Text] [Related]
33. Striatal and cortical neurochemical changes induced by chronic metabolic compromise in the 3-nitropropionic model of Huntington's disease. Blum D; Galas MC; Gall D; Cuvelier L; Schiffmann SN Neurobiol Dis; 2002 Aug; 10(3):410-26. PubMed ID: 12270701 [TBL] [Abstract][Full Text] [Related]
34. Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease. Lee ST; Chu K; Park JE; Kang L; Ko SY; Jung KH; Kim M Brain Res; 2006 Nov; 1118(1):199-207. PubMed ID: 16959224 [TBL] [Abstract][Full Text] [Related]
35. Neuroprotective activity of tetramethylpyrazine against 3-nitropropionic acid induced Huntington's disease-like symptoms in rats. Danduga RCSR; Dondapati SR; Kola PK; Grace L; Tadigiri RVB; Kanakaraju VK Biomed Pharmacother; 2018 Sep; 105():1254-1268. PubMed ID: 30021362 [TBL] [Abstract][Full Text] [Related]
36. Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: behavioural and histopathological characterisation. Fernagut PO; Diguet E; Stefanova N; Biran M; Wenning GK; Canioni P; Bioulac B; Tison F Neuroscience; 2002; 114(4):1005-17. PubMed ID: 12379255 [TBL] [Abstract][Full Text] [Related]
37. Lycopene modulates nitric oxide pathways against 3-nitropropionic acid-induced neurotoxicity. Kumar P; Kalonia H; Kumar A Life Sci; 2009 Nov; 85(19-20):711-8. PubMed ID: 19822156 [TBL] [Abstract][Full Text] [Related]
38. Structural and functional neuroprotection in a rat model of Huntington's disease by viral gene transfer of GDNF. McBride JL; During MJ; Wuu J; Chen EY; Leurgans SE; Kordower JH Exp Neurol; 2003 Jun; 181(2):213-23. PubMed ID: 12781994 [TBL] [Abstract][Full Text] [Related]
39. Oral Dyskinesias and striatal lesions in rats after long-term co-treatment with haloperidol and 3-nitropropionic acid. Andreassen OA; Ferrante RJ; Beal MF; Jørgensen HA Neuroscience; 1998 Dec; 87(3):639-48. PubMed ID: 9758230 [TBL] [Abstract][Full Text] [Related]
40. Tiagabine, a GABA uptake inhibitor, attenuates 3-nitropropionic acid-induced alterations in various behavioral and biochemical parameters in rats. Dhir A; Akula KK; Kulkarni SK Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):835-43. PubMed ID: 18234412 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]